Literature DB >> 6853672

Relationship between thyrotropin stimulation and radioiodine uptake in lung metastases of differentiated thyroid carcinoma.

M Schlumberger, P Charbord, P Fragu, P Gardet, J Lumbroso, C Parmentier, M Tubiana.   

Abstract

To examine whether the injection of bovine TSH (bTSH) produces maximal radioactive iodine uptake (RAIU) in lung metastases in patients with differentiated thyroid cancer, 10 patients were studied 12 times. In 10 of these studies, an initial RAIU measurement was performed immediately after 3 injections of 10 IU bTSH given immediately after T3 withdrawal. Another RAIU measurement was performed 7-19 days after T3 withdrawal. Uptake increased in all patients even when it was clearly detectable immediately after bTSH stimulation. Thus, 3 days of bTSH stimulation in these patients did not lead to maximal 131I uptake, and it could only be reached after prolonged endogenous TSH stimulation. bTSH was not injected in the 2 other patients, in whom 6 RAIU measurements were carried out. Radioiodine uptake increased with time in both patients. It appears that both the level of endogenous TSH and the length of stimulation play a determining role in RAIU. This might explain why 3 days of bTSH stimulation are insufficient to elicit maximal 131I uptake.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6853672     DOI: 10.1210/jcem-57-1-148

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.

Authors:  Deepa Rani; Sushma Kaisar; Sushma Awasare; Amit Abhyankar; Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-01       Impact factor: 9.236

2.  False positive 131I total body scan due to an ectasia of the common carotidis.

Authors:  D Giuffrida; M R Garofalo; G Cacciaguerra; V Freni; A Ippolito; C Regalbuto; M G Santonocito; A Belfiore
Journal:  J Endocrinol Invest       Date:  1993-03       Impact factor: 4.256

3.  Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas.

Authors:  T Saito; T Endo; A Kawaguchi; M Ikeda; R Katoh; A Kawaoi; A Muramatsu; T Onaya
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

4.  Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues.

Authors:  R Bruno; P Giannasio; G Ronga; E Baudin; J P Travagli; D Russo; S Filetti; M Schlumberger
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

5.  Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases.

Authors:  M Schlumberger; C Gicquel; J Lumbroso; F Tenenbaum; E Comoy; J Bosq; E Fonseca; P P Ghillani; B Aubert; J P Travagli
Journal:  J Endocrinol Invest       Date:  1992-10       Impact factor: 4.256

6.  Recombinant human thyrotropin-aided radioiodine therapy in patients with metastatic differentiated thyroid carcinoma.

Authors:  Ivana Zagar; Andreja A Schwarzbartl-Pevec; Barbara Vidergar-Kralj; Rika Horvat; Nikola Besic
Journal:  J Thyroid Res       Date:  2011-08-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.